Literature DB >> 10208538

Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines.

J M Peyrin1, C I Lasmézas, S Haïk, F Tagliavini, M Salmona, A Williams, D Richie, J P Deslys, D Dormont.   

Abstract

The scrapie isoform of the prion protein (PrPres) induces neurodegeneration and gliosis in the central nervous system. These features may be reproduced in vitro on exposure of neuronal and glial cultures to PrPres and the peptide HuPr P106-126. In the present study, we investigated the role of microglial cells and astrocytes in the pathological process by studying their molecular response to PrP 106-126 exposure. PrP 106-126 elicited a specific overproduction of pro-inflammatory cytokines IL1beta and IL6 in microglial cells (but not increased expression of TNFalpha, IL10, and TGFbeta1) and over-expression of GFAP in astrocytes. These effects were strictly dependent on the ability of the peptide to form amyloid fibrils. These data strongly suggest that microglial cells contribute to prion-related neurodegenerative processes by producing proinflammatory cytokines in the brain areas of amyloid PrP deposition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208538     DOI: 10.1097/00001756-199903170-00012

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  26 in total

Review 1.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

2.  Interaction between prion protein and interleukin-1A genes increases early-onset Alzheimer's disease risk.

Authors:  Onofre Combarros; Javier Llorca; Pascual Sánchez-Juan; Ignacio Mateo; Jon Infante; Eloy Rodríguez; Coro Sánchez-Quintana; José Berciano
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

3.  Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease.

Authors:  Colm Cunningham; David C Wilcockson; Delphine Boche; V Hugh Perry
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 4.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

5.  Effect of PrP105-132 on the secretion of interleukin-6 and interleukin-8 from microglial cells in vitro.

Authors:  Yun-Tian Yang; Shan Jin
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

6.  Aggregates of denatured proteins stimulate nitric oxide and superoxide production in macrophages.

Authors:  Szczepan Jozefowski; Janusz Marcinkiewicz
Journal:  Inflamm Res       Date:  2009-09-26       Impact factor: 4.575

7.  Role of interleukin-1 in prion disease-associated astrocyte activation.

Authors:  Julia Schultz; Anja Schwarz; Sabine Neidhold; Michael Burwinkel; Constanze Riemer; Dietrich Simon; Manfred Kopf; Markus Otto; Michael Baier
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

8.  Analysis of protein levels of 24 cytokines in scrapie agent-infected brain and glial cell cultures from mice differing in prion protein expression levels.

Authors:  Déborah Tribouillard-Tanvier; James F Striebel; Karin E Peterson; Bruce Chesebro
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

9.  Prion protein expression differences in microglia and astroglia influence scrapie-induced neurodegeneration in the retina and brain of transgenic mice.

Authors:  Lisa Kercher; Cynthia Favara; James F Striebel; Rachel LaCasse; Bruce Chesebro
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

10.  Synuclein activates microglia in a model of Parkinson's disease.

Authors:  Xiaomin Su; Kathleen A Maguire-Zeiss; Rita Giuliano; Landa Prifti; Karthik Venkatesh; Howard J Federoff
Journal:  Neurobiol Aging       Date:  2007-05-29       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.